Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 02 tags : Cancer save search
P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
Published: 2021-09-02 (Crawled : 16:00) - poseida.com
PSTX | $2.14 -11.93% 790K
|
Health Technology
|
| O: 3.27%
H: 0.0%
C: -4.98%
prostate cancer car-t cancer
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Published: 2021-09-02 (Crawled : 07:00) - globenewswire.com
TLSA | $0.44 31K
|
Health Technology
|
| O: 12.12%
H: 13.51%
C: 8.11%
DTIL | $13.06 3.7K
|
Health Technology
|
| O: 0.29%
H: 4.58%
C: 3.06%
treatment foralumab cancer antibody life science license car-t
Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1
Published: 2021-09-02 (Crawled : 01:00) - poseida.com
PSTX | $2.14 -11.93% 790K
|
Health Technology
|
| O: 3.27%
H: 0.0%
C: -4.98%
prostate cancer phase 1 therapy car-t cancer phase 2 phase 3 response t-cell
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.4801 107.75% 16M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
SPCB | $0.4278 55.0% 17M
|
Electronic Technology
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 38M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.5155 33.52% 3.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.